The following CONARIS product candidates have reached application in humans:
| Olamkicept | Drug candidate: IL-6 trans-signalling inhibitor (out-licensed to Ferring Pharmaceuticals) |
| CR12/01 | Drug candidate: gut microbiota modulator (small molecule) |
| CR12/02 | Drug candidate: gut microbiota modulator (small molecule) |
| CR13/01 | Drug candidate: intestinal microenvironment transfer / fecal filtrate transfer (sold in 2017) |
| CR19/01-04 | Gut microbiome-modulating dietary supplements (out-licensed in 2020) |
24 February, 2021